Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | BDKRB2 | P30411 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692741 | 0.89 | HDAC6 (0.40) | MEN1KMT2AHDAC6HDAC3HDAC4 | |
| SCHEMBL6692739 | 0.87 | MEN1 (0.40) | MEN1KMT2AHDAC6HDAC3HDAC4 | |
| SCHEMBL4050732 | 0.85 | RAB9A (0.38) | KMT2AALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL6692731 | 0.81 | MEN1 (0.40) | MEN1KMT2AHDAC6HDAC3HDAC4 | |
| SCHEMBL4052607 | 0.77 | MMP13 (0.43) | MEN1KMT2AKDM4EMAPT | |
| SCHEMBL4052583 | 0.76 | ADAM17 (0.48) | — | |
| SCHEMBL4050014 | 0.76 | MMP13 (0.59) | — | |
| SCHEMBL6688203 | 0.74 | MMP13 (0.51) | — | |
| SCHEMBL4050844 | 0.73 | MMP13 (0.41) | — | |
| SCHEMBL6694703 | 0.72 | P2RX7 (0.37) | HDAC6KDM4EALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397137-B1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | EP | claimed |
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2005-08-04 | — | — | US | claimed |
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2004-10-21 | — | — | US | claimed |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-10 | — | — | US | claimed |
| EP-1397137-B1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | EP | disclosed |
| US-7482372-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2005-08-04 | — | — | US | disclosed |
| US-6906053-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-6890915-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2004-10-21 | — | — | US | disclosed |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM8 | MEN1 1271/4885KMT2A 3634/4885HDAC6 225/4885 |
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM9 | MEN1 1044/4885KMT2A 3913/4885HDAC6 251/4885 |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM8 | MEN1 1271/4885KMT2A 3634/4885HDAC6 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.